Our results indicate that cfRNA could complement ctDNA‐guided real‐time therapy‐monitoring approaches for patients with mutant genotypes, and more importantly, cfRNA could provide an invaluable opportunity for wild‐type patients (∼20% of all melanomas) that otherwise would be missed by classical ctDNA mutations in BRAF/NRAS/TERT. This evidence concerns the gene NRAS and melanoma.